Found: 17
Select item for more details and to access through your institution.
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2012, v. 138, n. 11, p. 1821, doi. 10.1007/s00432-012-1259-2
- By:
- Publication type:
- Article
Publisher Correction: Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-33142-x
- By:
- Publication type:
- Article
Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-33142-x
- By:
- Publication type:
- Article
The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 6, p. 877, doi. 10.1111/bjh.16595
- By:
- Publication type:
- Article
High expression of cereblon ( CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 5, p. 695, doi. 10.1111/bjh.12338
- By:
- Publication type:
- Article
Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM.
- Published in:
- Cancers, 2021, v. 13, n. 23, p. 5886, doi. 10.3390/cancers13235886
- By:
- Publication type:
- Article
P-096: Tackling pyrimidine biosynthesis - CTP Synthase 1 is a novel target in the treatment of multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S91, doi. 10.1016/S2152-2650(21)02230-8
- By:
- Publication type:
- Article
The first-in-class BMI-1 modulators PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e113, doi. 10.1016/j.clml.2019.09.188
- By:
- Publication type:
- Article
Defining Clonal Plasticity Using Whole Exome Sequencing in Single Cells in an Index Case of amp1q21 Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e108, doi. 10.1016/j.clml.2017.03.196
- By:
- Publication type:
- Article
High IKAROS Expression in Bone Marrow Environmental, But Not in Myeloma Cells Predicts for Survival with Lenalidomide-Dexamethasone Therapy in Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e91, doi. 10.1016/j.clml.2017.03.162
- By:
- Publication type:
- Article
IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 3, p. 269, doi. 10.1002/ajh.24634
- By:
- Publication type:
- Article
Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
- Published in:
- Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0247-4
- By:
- Publication type:
- Article
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.
- Published in:
- Journal of Hematology & Oncology, 2015, v. 8, n. 1, p. 1, doi. 10.1186/s13045-014-0105-1
- By:
- Publication type:
- Article
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 3, p. 325, doi. 10.1111/j.1365-2141.2011.08689.x
- By:
- Publication type:
- Article
Correction to: MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-01007-9
- By:
- Publication type:
- Article